Prolastin c 1,000 MG/20 ML VLS
Ended Awarded
- Contract number
- SPE2DR26FQLL0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,845
Award facts
- Contract value 100% obligated
- $15,844.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $15,844.75 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Prolastin C 1,000 mg/20 ml vials. The delivery order, issued on November 17, 2025, with an ultimate completion date of December 9, 2025, represents a discrete pharmaceutical supply requirement under DMS Pharmaceutical Group's broader prime vendor contract. No small business set-aside designation was applied to this award, indicating that the contractor competed on an unrestricted basis within the Defense Logistics Agency's pharmaceutical procurement environment.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy that establishes multiple regional prime vendor contractors to support recurring pharmaceutical and medical supply needs across Department of Defense healthcare facilities worldwide. The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, with a ceiling value of $499,999,999 and completion date of December 31, 2036, authorizes the issuance of firm fixed-price delivery orders for branded and generic pharmaceuticals, biologics, and medical consumables. DMS Pharmaceutical Group has demonstrated substantial federal contracting capability through consistent performance on numerous delivery orders spanning multiple therapeutic categories, positioning the company as a critical supplier within the DoD's military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FQLL0?
SPE2DR26FQLL0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 17, 2025.
How much is contract SPE2DR26FQLL0 worth?
The government has obligated $15,845 on SPE2DR26FQLL0.
Is contract SPE2DR26FQLL0 an order under another contract?
Yes. SPE2DR26FQLL0 is a delivery order under SPE2DR25D9354, an indefinite delivery contract.
Was contract SPE2DR26FQLL0 competed?
The extent of competition for SPE2DR26FQLL0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award